Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTOP-B: Olanzapine 5 mg with standard triplet antiemetic therapy for prevention of CINV in breast cancer patients receiving AC
jRCT1031200134Completed
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Olanzapine 5 mg + standard triplet antiemetic therapy with Placebo + standard triplet antiemetic therapy (2 arms). Primary endpoint: Complete Response for all course. Started Oct 2020; status: completed.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT1031200134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031200134.